Over the last decade there has been an evident shift in outsourcing strategies across the pharmaceutical industry, secondary to heightened pressures concerning timelines and delivery of clinical trials. The ensuing increased workload and financial burden on R&D departments has encouraged a shift in attitude across the industry to a focus on increasing output and cutting costs. Furthermore, contract research organizations (CROs) have shown an increased presence in clinical research. This growth in CRO involvement has allowed the restructuring of the pharmaceutical industry’s R&D business models and has fuelled a fast growing competitive CRO landscape, with the most successful CROs building partnerships with pharma giants to sustain their growth. This white paper provides insight into the number of outsourcing opportunities available to these providers, as defined by CRO involvement in clinical trials, and how it has evolved over the past 10 years.
To finish reading this white paper, download the full paper here.